$1.96
+0.02 (+1.03%)
Open$1.92
Previous Close$1.94
Day High$2.00
Day Low$1.90
52W High$14.85
52W Low$1.70
Volume—
Avg Volume50.5K
Market Cap21.52M
P/E Ratio—
EPS$-4.34
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+329.6% upside
Current
$1.96
$1.96
Target
$8.42
$8.42
$5.85
$8.42 avg
$9.99
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.66M | 19.11M | 19.03M |
| Net Income | -1,423,753 | -1,667,488 | -1,447,772 |
| Profit Margin | -6.6% | -8.7% | -7.6% |
| EBITDA | -1,912,051 | -1,729,452 | -1,852,839 |
| Free Cash Flow | -992,506 | -967,985 | -917,697 |
| Rev Growth | +8.7% | -4.8% | +0.2% |
| Debt/Equity | 0.16 | 0.13 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |